CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DESVENLAFA	IDENTIFICATIO	*USP43–NF38*	1280	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
XINE	N/*A*.							*Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K or 197A
VORICONAZOLE	IDENTIFICATION/*A.*	*USP43–NF38*	4643	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197K? to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K
AMLODIPINE BESYLATE TABLETS	IDENTIFICATION/*A.*	*USP43–NF38*	286	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Spectroscopy: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
DACTINOMYCIN	IDENTIFICATION/*A.*	*USP43–NF38*	1227	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
TELMISARTAN TABLETS	IDENTIFICATION/*A.*	*USP43–NF38*	4240	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								197U: to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*:
NICOTINE TRANSDERMAL SYSTEM	PERFORMANCE TESTS/*Drug Release* <724>	*USP43–NF38*	3153	25-Sep-2020	1-Oct-2020	*NA*	*NA*	197U: In *Tests 1, 2, 4*, and *5*/ *Tolerances*: Change conform to *Dissolution* <711>, *Acceptance Table 1*. to: conform to *Acceptance Table 1*.
SODIUM IODIDE I 123 CAPSULES	*Radionuclide identification*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change A solution or suspension of 1 or more Capsules in water responds to the test for *Radionuclide identification*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								under *Sodium Iodide I 123 Solution*. to: (see *Radioactivity* <821>) The gamma-ray spectrum of a solution or suspension of 1 or more Capsules in water is identical to that of a specimen of ^{123}I of known purity that exhibits a major photoelectric peak having an energy of 0.159 MeV.
CARTEOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION	*Assay*	*USP43–NF38*	789	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change *pH 6.0 buffer*, *Mobile phase*, *Diluent*, *Standard preparation*, *Resolution solution*, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatographic system—Proceed as directed in the *Assay* under *Carteolol Hydrochloride*. to: *Buffer*, *Mobile phase*, *Standard stock solution*, *Standard solution*, *System suitability stock solution*, *System suitability solution*, *Chromatographic system*, and *System suitability*—Proceed as directed in the *Assay* under *Carteolol Hydrochloride*. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM IODIDE I 123 CAPSULES	*Other requirements*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Add *Diluent*—Prepare a mixture of *Buffer* and methanol (1:1). AND In all instances in *Procedure*: Change *Standard preparation* to: *Standard solution* Change *Other requirements* A solution or suspension prepared by homogenizing 1 or more Capsules in water to yield a concentration of not less than 1 MBq (25 µCi) per mL meets the requirements of the *Assay for*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								radioactivity under *Sodium Iodide I 123 Solution*. to: *Assay for radioactivity* Prepare a solution or suspension by homogenizing 1 or more Capsules in water to yield a concentration of not less than 1 MBq (25 µCi) per mL. Determine the radioactivity of the resulting solution using a suitable counting assembly, by use of a calibrated system as directed under *Radioactivity <821>*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM IODIDE I 123 CAPSULES	*Radionuclidic purity*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change A solution or suspension of 1 or more Capsules in water responds to the test for *Radionuclidic purity* under *Sodium Iodide I 123 Solution*. to: (see *Radioactivity* <821>) Using a suitable counting assembly, determine the radionuclidic purity of a solution or suspension of 1 or more Capsules in water: not less than 90% of the total radioactivity is present as I 123.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMIN D ASSAY	ASSAY/ *Chromatographic Methods*	*USP43–NF38*	6808	28-Aug-2020	1-Sep-2020	*NA*	*NA*	In the second Calculate statement in *Procedure 7/ Analysis/ Precholecalciferol and pre-ergocalciferol response factor*: Change pre-ergolecalciferol to: pre-ergocalciferol
CLOMIPRAMINE HYDROCHLORIDE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official July 08, 2020)*	Online	28-Aug-2020	1-Sep-2020	*NA*	*NA*	In USP Clomipramine Related Compound A RS: Change 458.89 to: 458.90
THEOPHYLLINE TABLETS	*Assay*	*USP43–NF38*	4328	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change *Mobile phase*, *Internal standard solution*, and *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prep aration—Prepare as directed in the *Assay* under *Theophylline*. to: *Buffer solution*—Transfer 2.72 g of sodium acetate trihydrate to a 2000-mL volumetric flask, add about 200 mL of water, and shake until dissolution is complete. Add 10.0 mL of glacial acetic acid, dilute with water to volume, and mix. *Mobile phase*—Transfer 70.0 mL of acetonitrile to a 1000-mL volumetric flask,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dilute with *Buffer solution* to volume, and mix. Degas, and filter before using. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer about 50 mg of theobromine, accurately weighed, to a 100-mL volumetric flask, dissolve in 10.0 mL of 6 N ammonium hydroxide, dilute with *Mobile phase* to volume, and mix. *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prep aration—Dissolve an accurately weighed quantity of USP Theophylline RS in *Mobile phase*, and dilute quantitatively, and stepwise if necessary, with *Mobile phase* to obtain a solution having a known concentration of about 1 mg per mL. Transfer 10.0 mL of this solution to a 100-mL volumetric flask, add 20.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mix to obtain a solution having a known concentration of about 0.1 mg of USP Theophylline RS per mL. AND Change *Chromatographic system* —Proceed as directed in the *Assay* under *Theophylline*. to: (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4-mm × 30-cm column that contains packing L1. The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 1.0 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between the theophylline and theobromine peaks is not less than 2.0, the tailing factor for the theophylline peak is not more than 2.0, and the relative standard deviation for replicate injections is not more than 1.5%. AND Change *Proce*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dure—Proceed as directed for *Procedure* in the *Assay* under *Theophylline*. to: *Proce dure* —Separately inject equal volumes (between 10 µL and 25 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, and measure the peak responses for the major peaks. The retention time of theophylline relative to that of theobromine is about 1.6.
SODIUM IODIDE I 123	*Radiochemical purity*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change Homogenize 1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								Capsule in 3 mL of water, add 3 mL of methanol, and centrifuge: the supernatant so obtained meets the requirements of the test for *Radiochemical purity* under *Sodium Iodide I 123 Solution*. to: Place a measured volume of a solution, containing 100 mg of potassium iodide, 200 mg of potassium iodate, and 1 g of sodium bicarbonate in each 100 mL, 25 mm from one end of a 25- × 300-mm strip of chromat

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ographic paper (*see Chromatography <621>*), and allow to dry. To the same area add a similar volume of the sample solution prepared as follows: homogenize the content from 1 Capsule in 3 mL of water and 3 mL of methanol and centrifuge. The supernatant should be diluted so that it provides a count rate of about 20,000 counts per minute. Allow the spots to dry. Develop the chromatogram over a period of about 4 hours

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								by ascending chromatography, using dilute methanol (7 in 10). Dry the chromatogram in air, and determine the radioactivity distribution by scanning with a suitable collimated radiation detector: the radioactivity of the iodide ^{123}I band is not less than 95.0% of the total radioactivity, and its R_F value falls within ±5.0% of the value found for sodium iodide when determined under similar conditions. Confirmation of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the identity of the iodide band is made by the addition to the suspected iodide band of 6 drops of acidified hydrogen peroxide solution (prepared by adding 6 drops of 1 N hydrochloric acid to 10 mL of hydrogen peroxide solution) followed by the dropwise addition of starch TS: the development of a blue color indicates the presence of iodide.
METHYLDOPA IDENTIFICATION HYDROCHLORIDE		*USP43–NF38*	2880	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *C*: Change It responds to *Identification*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								test *C* under Methyldopa. to: *Sample*: 10 mg *Analysis*: To the *Sample* add 0.15 mL of a solution of ninhydrin in sulfuric acid (1 in 250): a dark purple color is produced within 5–10 min. Add 0.15 mL of water. *Acceptance criteria*: The color changes to pale brownish yellow.
FUROSEMIDE TABLETS	*Assay*	*USP43–NF38*	2056	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change: *Mobile phase*, *Diluting solution*, *System suitability solution*, and *Chromatographic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								system—Prepare as directed in the test for *Related compounds* under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1000 mL, and mix. *System suitability solution* —Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing about 20 µg per mL and 12 µg per mL, respectively. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for *Procedure*: the resolution, *R*, between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for furosemide is at 254 nm.]
DIBASIC CALCIUM PHOSPHATE DIHYDRATE	IMPURITIES	*USP43–NF38*	708	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Chloride and Sulfate, Chloride* <221>: Change *Sample*: 0.2 g of of Dibasic Calcium Phosphate Dihydrate to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOTALOL HYD ROCHLORIDE TABLETS	*Identification*	*USP43–NF38*	4105	31-Jul-2020	1-Aug-2020	*NA*	*NA*	*Sample*: 0.2 g of Dibasic Calcium Phosphate Dihydrate Change Weigh and powder a quantity of the Tablets, equivalent to about 250 mg of sotalol hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter: the filtrate so obtained meets the requirements for *Identification* test B under *Sotalol*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride. to: *Thin-Layer Chromatographic Identification Test* <201>— *Test solution*—Weigh and powder a quantity of the Tablets, equivalent to about 250 mg of sotalol hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter. Use the filtrate. *Developing solvent system*: a mixture of chloroform and methanol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(70:30). *Proce dure*—Proceed as directed in the chapter, except to place two 25-mL beakers, each containing about 10 mL of ammonium hydroxide, on the bottom of the chromatogr aphic chamber that is lined with filter paper and contains the *Developing solvent system*, allow to equilibrate for 15 minutes, then place the plate in the chamber, and develop the chromatograms until the solvent front has moved about two-thirds

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the length of the plate: meets the requirements.
ANTI-FACTOR XA AND ANTI-FACTOR IIA ASSAYS FOR UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS	*Anti-Factor Xa and Anti-Factor IIa Assays for Low Molecular Weight Heparins*	*USP43–NF38*	6611	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change *Anti-Factor Xa Activity for Low Molecular Weight Heparin* to: The following procedure is used where specified in the individual monographs. This assay can be performed manually in plastic tubes utilizing heated block stations or water bath. Microtiter plate equipment with a reader and automated coagulometer can improve reproducibility and throughput.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acetic acid solution (stopping solution) is used for manual and microtiter plate assay. Automated coagulometers measure initial kinetic rate, and because of that, stopping of the reaction is not needed. *Anti-Factor Xa Activity for Low Molecular Weight Heparin*
DESIGN AND ANALYSIS OF BIOLOGICAL ASSAYS	COMBINATION OF INDEPENDENT ASSAYS/*Method 2*	*USP43–NF38*	6543	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In the second bullet in *Alternate weights* for inter-assay component of variation: Delete the duplicate equation
MINOCYCLINE HYDROCHLORIDE EXTENDE	PERFORMANCE TESTS/	*Revision Bulletin (Official September 01,*	Online	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Test 4*/*Table 5*: Change 45/Tablet and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
D-RELEASE TABLETS	*Dissolution <711>*	*2019)*						90 mg/Tablet to: 45 mg/Tablet and 90 mg/Tablet
FUROSEMIDE INJECTION	*Limit of furosemide related compound B*	*USP43–NF38*	2054	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change *Mobile phase*, *Diluting solution*, *System suitability solution* and *Chromatographic system*—Prepare as directed in the test for *Related compounds* under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to 1000 mL, and mix. *System suitability solution*—Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution containing about 20 µg per mL and 12 µg per mL, respectively. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylb

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								enzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								[NOTE—The response for furosemide is at 254 nm.]
ETHAMBUTOL HYDROCHLORIDE	IM PURITIES/*Limit of Aminobutanol*	*USP43–NF38*	1762	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Acceptance criteria*: Change The fluorescence intensity of the solution from the *Sample solution* is NMT 1.0% of the difference between the intensities of the two solutions. to: The fluorescence intensity of the solution from the *Sample solution* is NMT the difference between the intensities of the two solutions (NMT 1.0%).
FUROSEMIDE	*Limit of*	*USP43–NF38*	2056	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*furosemide related compound B*							*Mobile phase*, *Diluting solution*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the test for *Related compounds* under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to 1000 mL, and mix. *System suitability solution*—Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing about 20 µg per mL and 12 µg per mL, respectively.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatographic system (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for furosemide is at 254 nm.]
NUCLEIC ACID-BASED T		*USP43–NF38*	7865	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In footnote 1: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECHNIQUES—GENERAL	*Appendix 1*							http://ts.nist.gov/measurementservices/referencematerials/index.cfm. to: https://www.nist.gov/srm.
METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS	*USP43–NF38*	2918	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Labeling*: Change as metoprolol succinate $[(C_{15}H_{25}NO_3)_2 \cdot C_4H_6O_6]$. to: as metoprolol tartrate $[(C_{15}H_{25}NO_3)_2 \cdot C_4H_6O_6]$.
FUROSEMIDE INJECTION	*Assay*	*USP43–NF38*	2054	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change *Mobile phase*, *Diluting solution*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the test for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Related compounds under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to 1000 mL, and mix. *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability solution—Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing about 20 µg per mL and 12 µg per mL, respectively. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector capable of recording at both 254 nm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for furosemide is at 254 nm.]
ABIRATERONE ACETATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*Revision Bulletin (Official November 19, 2019)*	Online	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Analysis*: Change r_U = peak response of abiratrone acetate from the *Sample solution* r_S = peak response of abiratrone acetate from the *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: r_U = peak response of abiraterone acetate from the *Sample solution* r_S = peak response of abiraterone acetate from the *Standard solution*
ATROPINE SULFATE OPHTHALMIC OINTMENT	ASSAY/ *Procedure*	*USP43–NF38*	431	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Analysis*: Change atropine sulfate monohydrate, 694.83 to: atropine sulfate monohydrate, 694.84
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS	IM PURITIES/*Organic Impurities, Procedure 1/ Chromatographic system*	*Revision Bulletin (Official October 01, 2019)*	Online	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Detection solution*: Change Dissolve 1.25 g of potassium permanganate and 10.0 g of sodium hydroxide in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								500 mL of water (prepared fresh for each plate), and heat at 105° for 5 min. to: Dissolve 1.25 g of potassium permanganate and 10.0 g of sodium hydroxide in 500 mL of water (prepared fresh for each plate).
ATROPINE SULFATE	CHEMICAL INFORMATION	*USP43–NF38*	428	26-Jun-2020	1-Jul-2020	*NA*	*NA*	Change 694.83 to: 694.84
NOREPINEPHRINE BITARTRATE	CHEMICAL INFORMATION	*USP43–NF38*	3197	26-Jun-2020	1-Jul-2020	*NA*	*NA*	Change $C_8H_{11}NO_2 \cdot C_4H_6O_6$ to: $C_8H_{11}NO_3 \cdot C_4H_6O_6$
AMLODIPINE AND ATORVASTATIN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 27, 2019)*	Online	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In USP Atorvastatin Related Compound B RS: Change (3*S*,5*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt. to: Calcium (3*S*,5*R*)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); also known as (3*S*,5*R*)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE ORAL SOLUTION	*Assay*	*USP43–NF38*	1438	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Procedure*: Change (694.83/676.83)(25)$C_A(r_U/r_S)$ in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively; to: (694.84/676.82)(25)$C_A(r_U/r_S)$ in which 694.84 and 676.82 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively;
ATROPINE SULFATE INJECTION	ASSAY/ *Procedure*	*USP43–NF38*	430	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Analysis*: Change atropine sulfate monohydrate, 694.85 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								atropine sulfate monohydrate, 694.84 AND Change anhydrous atropine sulfate, 676.83 to: anhydrous atropine sulfate, 676.82
PROPYLENE CARBONATE	ASSAY/ *Procedure*/*Titrimetric system*	*USP43–NF38*	5986	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Mode*: Change Direct titration to: Residual titration
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	414	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In USP Atorvastatin Related Compound B RS: Change 3*S*,5*R* Isomer, or (3*S*,5*R*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*S*,5*R*)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); also known as 3*S*,5*R* Isomer, or (3*S*,5*R*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.
DIPHENOXYLATE HYDROCHLORIDE AND	*Assay*	*USP43–NF38*	1439	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Procedure*: Change 694.83/676.83)(

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATROPINE SULFATE TABLETS								250)$C_A(r_U/r_S)$ in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively; to: (694.84/676.82) (250)$C_A(r_U/r_S)$ in which 694.84 and 676.82 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively;
POWDERED BILBERRY EXTRACT	COMPOSITION	*USP43–NF38*	4813	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Content of Anthocyanosides and Anthocyanidins/System suitability/Resolution*: Change petunidin-3-*O*-arabinose

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FILGRASTIM	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	to: petu nidin-3-*O* -arabinoside In *Related Co mpoun ds*/*Standard solution*: Change 0.75 mg/mL of in water to: 0.75 mg/mL of USP Filgrastim RS in water AND In *Impurities with Charges Different from Filgra stim*/*Reference solution A*: Change 1 mg/mL of in water to: 1 mg/mL of USP Filgrastim RS in water AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In *Impurities with Charges Different from Filgrastim/Reference solution B*: Change Dilute *Reference solution A* with water to obtain a concentration of 20 µg/mL of . to: Dilute *Reference solution A* with water to obtain a concentration of 20 µg/mL of USP Filgrastim RS. AND In *Impurities with Charges Different from Filgrastim/Reference solution C*: Change 3 mg/mL of in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water to: 3 mg/mL of USP Filgrastim RS in water AND In *Impurities with Molecular Weight Different from That of Filgra stim/Reference solution A*: Change Dilute 25 µg of with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 250-µg/mL preparation of in 1X SDS sample buffer. to: Dilute 25 µg of USP Filgrastim RS with 25 µL of *4X SDS*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sample buffer and sufficient water to obtain 100 µL of a solution containing a 250-µg/mL preparation of USP Filgrastim RS in 1X SDS sample buffer. AND In *Impurities with Molecular Weight Different from That of Filgrastim/Reference solution B*: Change Prepare both a reduced and a nonreduced *Reference solution B* by diluting *Reference solution A* (1:100) with the appropriate 1X SDS sample

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								buffer to obtain a 2.5-µg/mL preparation of . to: Prepare both a reduced and a nonreduced *Reference solution B* by diluting *Reference solution A* (1:100) with the appropriate 1X SDS sample buffer to obtain a 2.5-µg/mL preparation of USP Filgrastim RS. AND In *Impurities with Molecular Weight Different from That of Filgra stim*/*Reference solution C*: Change Dilute 75 µg of with 25 µL of *4X*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								SDS sample buffer and sufficient water to obtain 100 µL of a solution containing a 750-µg/mL preparation of in 1X SDS sample buffer. to: Dilute 75 µg of USP Filgrastim RS with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 750-µg/mL preparation of USP Filgrastim RS in 1X SDS sample buffer. AND In *Limit of High Molecular Weight Proteins /Resolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change Dissolve about 1 mg of in 0.33 mL of 0.25 M sucrose, to: Dissolve about 1 mg of USP Filgrastim RS in 0.33 mL of 0.25 M sucrose, AND In *Limit of High Molecular Weight Proteins /Standard solution*: Change 0.3 mg/mL of in water to: 0.3 mg/mL of USP Filgrastim RS in water
TETRACAINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	4295	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Table 2*: Change Tetracaine hydrochloride related compound B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1.7 0.4 Tetracaine hydrochloride related compound C 2.1 0.4 to: Tetracaine related compound B 1.7 0.4 Tetracaine related compound C 2.1 0.4
PRAVASTATIN SODIUM	ADDITIONAL REQUIREMENTS	*USP43–NF38*	3645	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP Reference Standards <11>/USP Pravastatin Related Compound A RS*: Change 446.51 to: 446.52
FILGRASTIM	IDENTIFICATION/*C. Peptide Mapping*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Standard solution*: Change Prepare a solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing 80 µg of and 200 µL of *Digestion solution* to: Prepare a solution containing 80 µg of USP Filgrastim RS and 200 µL of *Digestion solution* AND In *System suitability requirements*: Change Eight major peaks should be present in each chromatogram as illustrated in the reference chromatogram provided with . to: Eight major peaks should be present in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								each chromatogram as illustrated in the reference chromatogram provided with USP Filgrastim RS.
ROPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	3943	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>/USP Ropivacaine Related Compound A RS: Change 2,6-Dimethylaniline hydrochloride. $C_8H_{12}ClN$ 157.64 [CAS-21436-98-6]. to: 2,6-Dimethylaniline hydrochloride. $C_8H_{11}N \cdot HCl$ 157.64 AND In USP Ropivacaine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Related Compound B RS: Change (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. $C_{17}H_{26}N_2O$ 328.89 to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate; (*R*)-*N*-(2,6-Dimethylphenyl)-1-propylp

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								iperidine-2-carboxamide hydrochloride monohydrate. $C_{17}H_{26}N_2O \cdot HCl \cdot H_2O$ 328.88
DESCRIPTION AND SOLUBILITY	REAGENTS AND REFERENCE TABLES/REFERENCE TABLES	*USP43–NF38*	6275	29-May-2020	1-Nov-2020	*NA*	*NA*	Change *Incommunicable Acid Hydrochloride*: to: *Aminolevulinic Acid Hydrochloride*:
ANHYDROUS DIBASIC CALCIUM PHOSPHATE	ASSAY/ *Procedure*	*Harmonization (Official December 01, 2019)*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Analysis*: Change *M* = actual molarity of the *Back-titrant* (mM/mL) to: *M* = actual molarity of the *Back-titrant* (mmol/mL) AND Change *F* = equivalency factor, 136.06 mg/mM

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *F* = equivalency factor, 136.06 mg/mmol
FILGRASTIM	ADDITIONAL REQUIREMENTS	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	Change *USP Reference Standards <11>* to: *USP Reference Standards <11>* USP Filgrastim RS
TRANYLCYPROMINE SULFATE	CHEMICAL INFORMATION	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	See https://www.usp nf.com/errata/tr anylcypromine-sulfate-image for correction.
METOPROLOL SUCCINATE	*USP Reference standards <11>*	*USP43–NF38*	2917	29-May-2020	1-Jun-2020	*NA*	*NA*	In USP Metoprolol Related Compound C RS: Change (±)4-[2-Hydroxy-3-(1-methylethyl)aminopropoxy]benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4-[2-Hydroxy-3-(isopropylamino)propoxy]benzaldehyde hydrochloride. $C_{13}H_{19}NO_3$ · HCl 273.76 AND In USP Metoprolol Related Compound D RS: Change (±) *N*,*N*-Bis[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl](1-methylethyl)amine. $C_{27}H_{41}NO_6$ 475.62 to: *N*,*N*-Bis{2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl}isopropylamine hydrochloride; also known as (±) *N*,*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FILGRASTIM	ASSAY/*Potency*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	-Bis[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl](1-methylethyl)amine hydrochloride. $C_{27}H_{41}NO_6$ · HCl 512.08 In *Standard solution*: Change 0.5 ng/mL of in *Medium B*. to: 0.5 ng/mL of USP Filgrastim RS in *Medium B*. AND In *Positive control solution*: Change 10 ng/mL of in *Medium B* to: 10 ng/mL of USP Filgrastim RS in *Medium B*

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- …
- Next page Next ›
- Last page Last »